Business context and reporting period
This is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the three months ended December 31, 2017, its fiscal first quarter of 2018. The filing describes a biotechnology business that produces and sells Keyhole Limpet Hemocyanin (KLH) for research and clinical applications. The supplied request metadata names Edesa Biotech, but the filing itself identifies Stellar Biotechnologies as the registrant.
Financial performance and position
| Metric | Quarter ended Dec. 31, 2017 | Comparable 2016 period |
|---|---|---|
| Revenue | $20,487 | $141,856 |
| Operating expenses | $1,410,366 | $1,556,332 |
| Operating loss | $1,389,879 | $1,414,476 |
| Net loss | $1,400,746 | $1,485,672 |
| Net loss per share, basic and diluted | $0.13 | $0.15 |
| Cash used in operating activities | $1,144,463 | $1,365,034 |
At December 31, 2017, cash and cash equivalents were $4.37 million, short-term Treasury investments were $999,000, and working capital was approximately $5.1 million. Total assets were $6.59 million; current liabilities were $574,376, comprising accounts payable and accrued liabilities. The filing reports no debt balance. Accumulated deficit was $46.8 million.
Material changes versus the prior period
- Revenue fell about 86% year over year, primarily because of lower product sales. Management said sales volumes vary with the progress and timing of customers’ clinical studies.
- Total expenses declined about 9%. Research and development rose to $631,034 from $460,865, driven mainly by manufacturing scalability and throughput work. General and administrative expense decreased to $678,481 from $932,067, reflecting cost reductions including lower salaries, professional fees, travel, legal fees, and public-company expenses.
- Net loss narrowed to $1.40 million from $1.49 million. Operating cash use also declined year over year. Cash and cash equivalents decreased $201,280 during the quarter; investing activities provided $961,059, principally from $1.0 million in investment maturities and sales.
Outlook, risks, contingencies, and unusual items
- Management expects continuing losses and says cash on hand and product sales are expected to fund operations for the next 12 months; additional capital will be needed to pursue the business plan beyond February 2019. No new financing was committed, and availability on acceptable terms is not assured. The company may adjust spending and is evaluating debt or equity financing, including possible strategic arrangements. Its effective shelf registration permits further offerings subject to applicable limits.
- Revenue is concentrated: 98% came from three customers in the quarter, compared with 92% from one customer a year earlier. Europe represented 73% of revenue and North America 27%.
- The Neostell joint-venture milestone deadline passed on December 31, 2017. The parties expressed a mutual desire to renew and amend the agreement to extend the timeline; the filing does not report that an amendment was completed. Stellar holds a 30% interest and may need to provide further pro rata financing.
- On January 30, 2018, Nasdaq notified the company that it did not meet the $1.00 minimum bid-price requirement. The company had until July 30, 2018 to regain compliance; delisting remained a risk if it failed to do so.
- Lease commitments totaled $333,000 at December 31, 2017, and purchase commitments were approximately $133,000, expected to be fulfilled within 12 months. The filing reports no material off-balance-sheet arrangements or material legal proceedings outside the ordinary course.
- Management concluded disclosure controls were effective as of December 31, 2017 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm current cash runway, operating burn, and any financing completed after the filing; management disclosed no committed new financing.
- Track KLH sales, customer clinical-trial progression, and customer concentration, given the sharp revenue decline and dependence on a small customer base.
- Check whether the Neostell agreement was renewed or amended and whether the joint venture requires additional funding.
- Verify the outcome of Nasdaq’s minimum-bid-price deficiency and any resulting listing or capital-raising implications.
- Review subsequent filings for changes in commitments, liquidity, and the company’s going-concern plans.